Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, PRAStaff@fda.hhs.gov.
End Further Info
Start Supplemental Information
The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for Start Printed Page 60094each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at https://www.reginfo.gov/public/do/PRAMain. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
Table 1—List of Information Collections Approved By OMB
|Title of Collection||OMB control No.||Date approval expires|
|Agreement for Shipment of Devices for Sterilization||0910-0131||9/30/2022|
|Substances Prohibited from Use in Animal Food or Feed; Animal Proteins Prohibited in Ruminant Feed||0910-0339||9/30/2022|
|Clinical Laboratory Improvement Amendments Waiver Applications||0910-0598||9/30/2022|
|Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments and Listing of Ingredients in Tobacco Products||0910-0650||9/30/2022|
|Tobacco Health Document Submission||0910-0654||9/30/2022|
|Guidance for Industry and Food and Drug Administration Staff; Section 905(j) Reports: Demonstrating Substantial Equivalence Requirements for Tobacco Products||0910-0673||9/30/2022|
|Exemptions From Substantial Equivalence Requirements for Tobacco Products||0910-0684||9/30/2022|
|Evaluation of the Program for Enhanced Review Transparency and Communication for New Molecular Entity New Drug Applications and Original Biologics License Applications in Prescription Drug User Fee Acts and 351(k) Biologics License Applications in Biosimilars User Fee Act||0910-0746||9/30/2022|
|Medical Device Accessories||0910-0823||9/30/2022|
End Supplemental Information
Dated: October 29, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-24263 Filed 11-6-19; 8:45 am]
BILLING CODE 4164-01-P